1. In Vivo
  2. >>Business Strategy

Abbott Moves One Way in Cardiovascular Devices, Another in Orthopedics, To Get To the Same Place

Abbott Laboratories broke into the spinal market with its acquisition of Spinal Concepts, and expanded its interventional cardiology product line by acquiring Jomed's coronary and peripheral interventional product lines. Both deals reflect the increasing convergence in medical devices of drug and device therapies.

Rumors about Abbott Laboratories Inc. 's acquisition of struggling European cardiovascular device company Jomed NV [See Deal] were all over this year's Paris Course on Revascularization (PCR) meeting, held in early May just weeks before the news officially broke. One report had Abbott paying a significant premium for the troubled company, well more than it's estimated break-up value of $75 million. Another report had Abbott and Jomed doing a three-way deal with vulnerable plaque start-up Volcano Therapeutics Inc. , with the latter walking off with the intravascular ultrasound (IVUS) business Jomed got when it acquired EndoSonics Corp. a couple of years ago [See Deal].

Of course, Abbott's eventual price paid, nearly $71 million plus the assumption of some liability (more than $20 million), was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.